Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/76004
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial |
Author: | Sur, D. Kanungo, S. Sah, B. Manna, B. Ali, M. Paisley, A.M. Niyogi, S.K. Park, J.K. Sarkar, B. Puri, M.K. Kim, D.R. Deen, J.L. Holmgren, J. Carbis, R. Rao, R. Thu Van, N. Han, S.H. Attridge, S. Donner, A. Ganguly, N.K. et al. |
Citation: | PLoS Neglected Tropical Diseases, 2011; 5(10):e1289-1-e1289-6 |
Publisher: | Public Library of Science |
Issue Date: | 2011 |
ISSN: | 1935-2735 1935-2735 |
Editor: | Ryan, E.T. |
Statement of Responsibility: | Dipika Sur ... Stephen Attridge ... et al. |
Abstract: | BACKGROUND: Killed oral cholera vaccines (OCVs) have been licensed for use in developing countries, but protection conferred by licensed OCVs beyond two years of follow-up has not been demonstrated in randomized, clinical trials. METHODS/PRINCIPAL FINDINGS: We conducted a cluster-randomized, placebo-controlled trial of a two-dose regimen of a low-cost killed whole cell OCV in residents 1 year of age and older living in 3,933 clusters in Kolkata, India. The primary endpoint was culture-proven Vibrio cholerae O1 diarrhea episodes severe enough to require treatment in a health care facility. Of the 66,900 fully dosed individuals (31,932 vaccinees and 34,968 placebo recipients), 38 vaccinees and 128 placebo-recipients developed cholera during three years of follow-up (protective efficacy 66%; one-sided 95%CI lower bound = 53%, p<0.001). Vaccine protection during the third year of follow-up was 65% (one-sided 95%CI lower bound = 44%, p<0.001). Significant protection was evident in the second year of follow-up in children vaccinated at ages 1–4 years and in the third year in older age groups. CONCLUSIONS/SIGNIFICANCE: The killed whole-cell OCV conferred significant protection that was evident in the second year of follow-up in young children and was sustained for at least three years in older age groups. Continued follow-up will be important to establish the vaccine's duration of protection. |
Rights: | © 2011 Sur et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
DOI: | 10.1371/journal.pntd.0001289 |
Published version: | http://dx.doi.org/10.1371/journal.pntd.0001289 |
Appears in Collections: | Aurora harvest 7 Molecular and Biomedical Science publications |
Files in This Item:
File | Size | Format | |
---|---|---|---|
hdl_76004.pdf | 445.41 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.